Business Description
Indaptus Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US45339J1051
Description
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 68.34 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -43 | |||||
| 3-Year EPS without NRI Growth Rate | -40.3 | |||||
| 3-Year FCF Growth Rate | -37.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 30.79 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.21 | |||||
| 9-Day RSI | 36.65 | |||||
| 14-Day RSI | 39.41 | |||||
| 6-1 Month Momentum % | -42.3 | |||||
| 12-1 Month Momentum % | -34.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.42 | |||||
| Quick Ratio | 3.42 | |||||
| Cash Ratio | 3.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.8 | |||||
| Shareholder Yield % | -31.75 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -152.17 | |||||
| ROA % | -124.06 | |||||
| ROIC % | -926.81 | |||||
| ROC (Joel Greenblatt) % | -10167.99 | |||||
| ROCE % | -156.26 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.75 | |||||
| Price-to-Tangible-Book | 1.75 | |||||
| EV-to-EBIT | -0.21 | |||||
| EV-to-EBITDA | -0.21 | |||||
| EV-to-FCF | -0.28 | |||||
| Price-to-Net-Current-Asset-Value | 1.94 | |||||
| Price-to-Net-Cash | 2.06 | |||||
| Earnings Yield (Greenblatt) % | -476.19 | |||||
| FCF Yield % | -109.77 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INDP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Indaptus Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.71 | ||
| Beta | 1.12 | ||
| Volatility % | 53.7 | ||
| 14-Day RSI | 39.41 | ||
| 14-Day ATR ($) | 0.113479 | ||
| 20-Day SMA ($) | 1.115 | ||
| 12-1 Month Momentum % | -34.14 | ||
| 52-Week Range ($) | 0.84 - 3.1 | ||
| Shares Outstanding (Mil) | 12.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Indaptus Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Indaptus Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Indaptus Therapeutics Inc Frequently Asked Questions
What is Indaptus Therapeutics Inc(INDP)'s stock price today?
The current price of INDP is $1.03. The 52 week high of INDP is $3.10 and 52 week low is $0.84.
When is next earnings date of Indaptus Therapeutics Inc(INDP)?
The next earnings date of Indaptus Therapeutics Inc(INDP) is 2025-03-13 Est..
Does Indaptus Therapeutics Inc(INDP) pay dividends? If so, how much?
Indaptus Therapeutics Inc(INDP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers